Skip to main content

Advertisement

SpringerLink
Log in

Extraintestinal manifestations of inflammatory bowel disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Patients with inflammatory bowel disease (IBD) may confront a variety of nonintestinal problems. The first North American population-based data describing the incidence rates of several of these disorders have been reported over the past year. Reports have also documented our expanding knowledge of peristomal pyoderma gangrenosum, and of ulcerative colitis following liver transplantation in patients with primary sclerosing cholangitis. Osteopenia continues to receive considerable attention. Factors such as osteoprotegrin ligand, and its interaction with receptor activator of nuclear factor kappa B, are connected with T-cell activity, inflammation, and osteoclastogenesis. Studies in these and other areas are addressed in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116–1122. This is the first North American population-based study assessing the prevalence of PSC, ankylosing spondylitis, iritis, uveitis, pyoderma gangrenosum, and erythema nodosum in IBD.

    Article  PubMed  CAS  Google Scholar 

  2. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A: The epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149:916–924.

    PubMed  CAS  Google Scholar 

  3. Tromm A, May D, Almus E, et al.: Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 2001, 39:137–144.

    Article  PubMed  CAS  Google Scholar 

  4. Friedman S, Marion JF, Scherl E, et al.: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:1–7.

    Article  PubMed  CAS  Google Scholar 

  5. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC: Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000, 135:564–568.

    Article  PubMed  CAS  Google Scholar 

  6. Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000, 284:1546–1548.

    Article  PubMed  CAS  Google Scholar 

  7. Kelly P, Patchett S, McCloskey D, et al.: Sclerosing cholangitis, race and sex. Gut 1997, 41:688–689.

    Article  PubMed  CAS  Google Scholar 

  8. Terjung B, Herzog V, Worman HJ, et al.: Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332–340.

    Article  PubMed  CAS  Google Scholar 

  9. Terjung B, Spengler U, Sauerbach T, Worman HJ: ‘Atypical p-ANCA‘ in IBD and hepatobiliary disorders reacts with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310–322. This study defines the myeloid nuclear antigen(s) to which pANCA in IBD binds.

    Article  PubMed  CAS  Google Scholar 

  10. Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case control study. Hepatology 1998, 27:311–316.

    Article  PubMed  CAS  Google Scholar 

  11. Herzog K, Goldblum JR: Gall bladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Mod Pathol 1996, 9:194–198.

    PubMed  CAS  Google Scholar 

  12. Rasmussen HH, Fallingborg JF, Mortensen PB, et al.: Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol 1997, 32:604–610.

    Article  PubMed  CAS  Google Scholar 

  13. Heikius B, Niemela S, Lehtola J, et al.: Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol 1997, 32:153–161.

    PubMed  CAS  Google Scholar 

  14. Heikius B, Niemela S, Lehtola S, Karttunen TJ: Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol 1999, 94:1062–1079.

    Article  PubMed  CAS  Google Scholar 

  15. Papatheodoridis GV, Hamilton M, Mistry PK, et al.: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998, 43:639–644.

    Article  PubMed  CAS  Google Scholar 

  16. Schoon EJ, Muller MCA, Vermeer C, et al.: Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: another pathogenetic factor of osteoporosis in Crohn’s disease? Gut 2001, 48:473–477.

    Article  PubMed  CAS  Google Scholar 

  17. Binkley NC, Suttie JW: Vitamin K nutrition and osteoporosis. J Nutr 1995, 125:1812–1821.

    PubMed  CAS  Google Scholar 

  18. Carraballo PJ, Heit JA, Atkinson EJ, et al.: Long term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159:1750–1756.

    Article  Google Scholar 

  19. Kong Y-Y, Boyle WJ, Penninger JM: Osteoprotegrin ligand: a regulator of immune response and bone physiology. Immunol Today 2000, 21:495–502. This is a review of the biology of OPGL, a molecule that may be an important link between osteoclastogenesis (and hence osteoporosis) and T-cell biology (and hence systemic inflammation).

    Article  PubMed  CAS  Google Scholar 

  20. Bernstein CN: Risk factors and prevalence of bone disease in inflammatory bowel disease. In Trends in Inflammatory Bowel Disease Therapy, 1999. Edited by Williams CN, Bursey RF, Gall DG, et al. Dordrecht: Kluwer Academic Publishers; 1999:147–162.

    Google Scholar 

  21. Schoon EJ, van Nunen AB, Wouters RSME, et al.: Osteopenia and osteoporosis in Crohn’s disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 2000, 35(suppl 232):43–47.

    Google Scholar 

  22. Schoon EJ, Blok BM, Geerling BJ, et al.: Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000, 119:1203–1208.

    Article  PubMed  CAS  Google Scholar 

  23. Vestergaard P, Krogh K, Rejnmark L, et al.: Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis. Gut 2000, 46:176–181.

    Article  PubMed  CAS  Google Scholar 

  24. Bernstein CN, Blanchard JF, Leslie W, et al.: The incidence of fractures among patients with IBD: a population-based study. Ann Intern Med 2000, 133:795–799. This is the first population-based study reporting the incidence of fractures in patients with IBD. The incidence is quantified at approximately one fracture/100 patient-years. Compared with a matched cohort, there was a 40% increased risk of sustaining a fracture.

    PubMed  CAS  Google Scholar 

  25. Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000, 119:639–646.

    Article  PubMed  CAS  Google Scholar 

  26. Schulte CMS, Dignass AU, Goebell H, et al.: Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119:909–920. This interesting study attempted to correlate cytokine genotyping for proinflammatory cytokines with rate of annual bone loss.

    Article  PubMed  CAS  Google Scholar 

  27. Bernstein CN, Blanchard JF, Houston D, Wajda A: The incidence of venous thromboembolic disease among patients with IBD: a population-based study. Thromb Haemost 2001, 85:430–434. This is the first population-based study reporting the incidence of venous thromboembolism in patients with IBD. The incidence is quantified at approximately one venous thrombosis/200 patientyears. Compared with a matched cohort, there was a threefold to fourfold increased risk of sustaining DVT/PE.

    PubMed  CAS  Google Scholar 

  28. Guedon C, Le Cam-Duchez V, Lalaude O, et al.: Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis. Am J Gastroenterol 2001, 96:1448–1454.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. John Buhler Research Centre, University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, MD804F-715 McDermot Avenue, R3E-3P4, Winnipeg, Manitoba, Canada

    Charles N. Bernstein MD

Authors
  1. Charles N. Bernstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernstein, C.N. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 3, 477–483 (2001). https://doi.org/10.1007/s11894-001-0068-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-001-0068-6

Keywords

Search

Navigation